ANN ARBOR, Mich. – February 2, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that Bruce A. Goldsmith, Ph.D., Chief Business Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 11:15 a.m. Eastern Time. The conference… Read More

Findings supporting novel approaches to inhibit or enhance immune responses for treating autoimmunity and cancer published in Nature Chemical Biology. ANN ARBOR, Mich. – Jan 5, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat autoimmune diseases and cancer, today announced publication of research showing that sterols and sterol sulfates formed during… Read More

Results presented in poster presentation beginning today and in oral presentation Saturday November 8 at 1:40 PM at Society for Immunotherapy of Cancer annual meeting. ANN ARBOR, Mich. – November 7, 2014 – Lycera Corp., a biopharmaceutical company developing breakthrough oral immune modulators to treat autoimmune disease and cancer, today announced that data on the… Read More

Data to be presented in poster presentation beginning Friday November 7; selected for oral presentation Saturday November 8 at 1:40 PM in Exhibit Hall C. ANN ARBOR, Mich. – October 31, 2014 – Lycera Corp., a biopharmaceutical company developing breakthrough oral immune modulators to treat autoimmune disease and cancer, today announced that data on the… Read More

ANN ARBOR, Mich. – August 8, 2014 – Lycera Corp., a biopharmaceutical company pioneering the development of breakthrough oral medicines to treat autoimmune disease and cancer based on the science of immune modulation, today announced the appointment of Harinder Singh, Ph.D., as chair of the company’s scientific advisory board. Dr. Singh will lead the board’s… Read More

ANN ARBOR, Mich. – April 29, 2013 – Lycera Corp., a biopharmaceutical company pioneering the development of breakthrough oral medicines to treat autoimmune diseases, today announced the appointment of Bruce A. Goldsmith, Ph.D., as chief business officer. In this new position, Dr. Goldsmith will work as part of the executive team to implement the company’s… Read More

ANN ARBOR, Mich. – April 1, 2013 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing breakthrough oral medicines to treat autoimmune diseases, today announced the appointment of Laura L. Carter, Ph.D. to vice president, biology. “I am pleased to welcome Dr. Carter to the Lycera team,” said Kathleen M. Metters, Ph.D., Lycera… Read More

Collaboration to Focus Strategically on Novel Treatments for Autoimmune Disease ANN ARBOR, Mich. – February 12, 2013 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing breakthrough oral medicines to treat autoimmune diseases, today announced a collaboration agreement with Merck, known as MSD outside the United States and Canada, to discover, develop and… Read More

Steven Gillis, Ph.D., Managing Director of ARCH Venture Partners, Named Chairman of the Board; Michael Steinmetz, Ph.D., of Clarus Ventures to Join Board ANN ARBOR, Mich. – February 15, 2012 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that Steven Gillis, Ph.D., managing… Read More